Jump to content

pacestick

Member
  • Posts

    341
  • Joined

  • Last visited

Everything posted by pacestick

  1. Its hard to start a vaccination programme without vaccine by that I mean it had to be developed and priority was always going to go to those wealthy countries with high infection/death rates However I agree with the rest of your post
  2. well the kiwis are enjoying it anyway . Barnaby Joyce is the the number two nominated person to be new zealander of the year 2018
  3. Expect a move to taxation by distance travelled so much a kilometre
  4. sorry should have posted second half 2017
  5. Goldman sachs presentation New York http://www.beachenergy.com.au/irm/PDF/6513...InvestmentForum Note the excess gas destined for the spot market second half 2016
  6. Based on the increase POO I am expecting a small increase in the dividend compared to the last half .
  7. adr comparison web site http://stockpar.com/index.php?id=2
  8. pacestick

    UNS

    I have no idea . They have dealt with the immediate short term financial crisis . There will be more contracts to come both from AMGEN and others over the next twelve months as the company edges towards profitability
  9. pacestick

    UNS

    Unilife and Amgen Enter Strategic Collaboration for Injectable Drug Delivery Systems Amgen to invest up to $75 million in leading technology platform Collaboration includes license agreement and master development and supply agreement YORK, Pa., Feb. 22, 2016 /PRNewswire/ -- Unilife Corporation (NASDAQ: UNIS, ASX: UNS) today announced a strategic collaboration with Amgen (NASDAQ: AMGN), a leading biotechnology company, for injectable drug delivery systems. The collaboration, which includes licensing, investment, development and supply agreement components, is centered upon the use of Unilife's portfolio of prefilled, customizable wearable injectors for medicines to enhance the patient experience. Under the terms of the collaboration, Unilife has granted Amgen exclusive rights to Unilife's wearable injectors within select drug classes for use with certain Amgen assets, while preserving rights previously granted to other Unilife customers. Unilife has also granted Amgen non-exclusive rights to all proprietary Unilife delivery systems within the therapeutic areas of oncology, inflammation, bone health, nephrology, cardiovascular and neuroscience. "Unilife looks forward to a long-term strategic collaboration with Amgen to drive value for patients, prescribers and payers," said Ian Hanson, senior vice president and general manager of Unilife's Wearable Injector business unit. "Unilife is pleased to advance its leadership position in the wearable injectors market to meet growing demand for biologics and other medicines. Our prefilled, pre-assembled and ready-to-inject delivery systems are easy-to-use and enhance patient experience." "We are pleased to enter this collaboration with Unilife," said Alison Moore, senior vice president of Process Development at Amgen. "One important pillar of Amgen's strategy is to invest in leading drug delivery technologies to more effectively meet the needs of patients suffering from serious illnesses. Unilife continues to develop technology that could provide patients with innovative and meaningful enhancements to drug administration." Under the strategic collaboration, Unilife can receive up to $75 million. At closing, Amgen paid a nonrefundable $20 million license fee and purchased a $30 million senior secured convertible note from Unilife. Amgen may purchase up to an additional $25 million in senior secured convertible notes over the next two years ($15 million in January 2017 and $10 million in January 2018). These payments are in addition to Amgen's $15 million payment to Unilife in connection with the exclusivity letter entered into on December 31, 2015. In addition to these payments, Unilife expects to generate future revenue from the strategic collaboration with Amgen. The collaboration includes a master development and supply agreement that captures key terms for the development, production and supply of Unilife delivery systems. Development programs will commence in 2016. About Unilife Unilife Corporation (NASDAQ: UNIS / ASX: UNS) is a U.S.-based developer and commercial supplier of injectable drug delivery systems. Unilife's portfolio of innovative, differentiated products includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, insulin delivery systems, ocular delivery systems and novel systems. Products within each platform are customizable to address specific customer, drug and patient requirements. Unilife's global headquarters and manufacturing facilities are located in York, Penn. For more information, visit www.unilife.com General: UNIS-G Investor Contacts (U.S.): Investor Contacts (Australia) Todd Fromer / Garth Russell Jeff Carter KCSA Strategic Communications Unilife Corporation P: + 1 212-682-6300 P: + 61 2 8346 6500 Forward-Looking Statements This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K, those described in the "Risk Factors" set forth in Unilife's prospectus supplement, dated as of and filed with the U.S. Securities and Exchange Commission on February 22, 2016, and those described from time to time in other reports which we file with the U.S. Securities and Exchange Commission. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/un...-300223649.html SOURCE Unilife Corporation
  10. <h2 class="hd">Search Results</h2> â–º 2:55<h3 class="r" style="font-size:18px"> </h3>youtube death star canteen 2 darth vader death star canteen-eddie izzard eddie izzard death star canteen download lego star wars cafeteria darth vader cafeteria jeff vader youtube to mp3 youtube funny
  11. pacestick

    UNS

    I would be surprised if AMGN -UNS deal is the only one going on the ASX at the moment, but I would be amazed if AMGEN UNIS deal is the only one going on with AMGN on the Nasdaq . AMGN is a very large company in a very healthy financial position with a very large number of activities occurring
  12. pacestick

    UNS

    why would they pay 15 million non refundable and walk away. A lways possible I suppose if not getting what they want but not I would think very likely. AS to it being over by the 31st as per the original release I would point out that the result of the Morgan Stanley negotiations was due by 31 December but there was no announcement before 4 January. So I will not be concerned if the announcement does not come before the end of next week.
  13. http://www.bloomberg.com/news/articles/201...il-to-the-world Before the most recent round of sanctions went into effect three years ago, Iran was able to sell oil to 21 countries. By mid-2012, that was down to six: China, India, Japan, South Korea, Taiwan, and Turkey. Rather than immediately pull back on production, and risk damaging oil wells by slowing them down, Iran decided to store its excess crude. As it scrambled to build onshore tanks, the government loaded millions of barrels onto its suddenly out-of-work fleet of crude-carrying vessels. The Iranians eventually reduced their oil output by about a third, to a low of 2.5 million barrels a day in mid-2013, according to data compiled by Bloomberg. As exports fell to 1 million to 1.5 million barrels a day, Iran kept filling its tankers with oil it couldn’t sell. By this summer, a large portion of its tanker fleet, one of the world’s biggest, sat parked off the coast, filled with 50 million to 60 million barrels of crude and condensate, a lighter form of oil used to make petrochemicals. http://assets.bwbx.io/images/i4v6..gVUF5g/v1/-1x-1.jpg Since the nuclear agreement between Iran and six other nations was reached on July 14, the regime has been preparing to ramp up its exports and sell that stored oil. A small number of Iranian tankers believed to have been storing crude has left the Persian Gulf in the past several weeks, according to data compiled by Bloomberg. Three of those ships have since disappeared from detection by failing to report their location. Iran’s crude output has been rising for two years and now stands at about 2.9 million barrels a day, the highest level since 2012. It won’t be allowed to sell that extra crude until sometime next year, when the International Atomic Energy Agency verifies that Iran has complied with curbs on its nuclear program. The monitoring needed for that to happen probably won’t be in place until January or February, say three Western diplomats familiar with the nuclear monitoring process. Oil Minister Bijan Namdar Zanganeh says sanctions will be lifted sooner. When they are, he says, production will rise immediately by a half-million barrels per day, and after four to five months, by an additional half-million barrels. He says that by then, “we will reach to a figure between 3.8 and 3.9 million barrels a day.†Saudi Arabia is pumping 10.5 million barrels daily. Even if Iran can increase production as quickly as Zanganeh claims, it may have to incentivize buyers by offering lower prices or by trading oil for goods or services, says Sara Vakhshouri, president of SVB Energy International, an energy consulting group in Washington. That’s because the Saudis have used long-term contracts to lock in customers who not long ago bought Iranian oil. The sanctions put in place in 2012 shrank the economy by about 10 percent by March 2014, according to the U.S. Congressional Research Service. A report by Anthony Cordesman of the Center for Strategic & International Studies in Washington estimates that Iran needs about $170 billion to develop its oil and gas potential. The decline in oil prices has led to a drop in Iran’s own investment in its oil and gas sectorâ€â€ÂÂÂÂfrom $40 billion in 2011 and 2012 combined to only $6 billion last year, Zanganeh says. The International Energy Agency estimates about half of Iranian production comes from oil fields that are more than 70 years old. Much of the money Iran has made through its remaining crude exports since 2012 is being held in escrow accounts in the various countries still buying Iranian crude. To reduce Iran’s access to cash, Congress passed a law requiring that Iran spend oil revenue only on goods from its customer countries. The Department of the Treasury estimates Iran will be able to retrieve half that amount, or about $56 billion. That’s still not enough to restart full oil production. And so the government is looking for foreign investment. Since July, political and business delegations from Austria, Germany, Italy, and Spain have visited Tehran. “I think European companies are very eager to be involved in our projects,†Zanganeh says. Iran has not met with U.S. companies, he says. “It seems they have received the order from the U.S. government not to have the meeting. The doors are open for them like others.†Some Iran watchers say Western companies will proceed with caution. “You’re not going to see an energy gold rush in terms of capital investment in Iran anytime soon,†says Mark Dubowitz, executive director of the Foundation for Defense of Democracies in Washington and a supporter of tougher sanctions. “The majors are still reluctant to make multibillion-dollar commitments to Iran.†â€â€ÂÂÂÂWith Jonathan Tirone, Julian Lee, and Grant Smith The bottom line: Iran says it will be pumping 3.9 million barrels a day by March, but its oil fields are old and need investment.
  14. pacestick

    UNS

    Unilife Announces Review of Strategic Alternatives Morgan Stanley Appointed as Strategic Advisor in Response to Expressions of Interest from Third Parties YORK, Pa., Sept. 2, 2015 /PRNewswire/ -- Unilife Corporation ("Unilife" or the "Company") (NASDAQ: UNIS and ASX: UNS), a developer, manufacturer and supplier of injectable drug delivery systems, today announced that in response to third-party initiated expressions of interest, the Company's Board of Directors has engaged Morgan Stanley & Co. LLC to conduct a review of strategic alternatives to maximize shareholder value. Potential strategic alternatives to be explored and evaluated during the review process may include a possible sale of the Company, a strategic partnership with one or more parties or the licensing of some of the Company's proprietary technologies. The Unilife Board of Directors will not provide any commitment regarding when or if this strategic review process will result in any type of transaction, and no assurance can be given that the Company will determine to pursue a potential sale, strategic partnership or licensing arrangement. Mr. Alan Shortall, Chairman and CEO of Unilife, said: "In keeping with the Board's commitment to act in the best interests of all shareholders, we have determined at this time that it is prudent to explore strategic alternatives to determine the best opportunities for enhancing shareholder value. Unilife management will continue to operate the business as normal during this review process to serve the needs of existing and prospective pharmaceutical customers." About Unilife Corporation Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife's portfolio of innovative, differentiated products includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto injectors, wearable injectors, insulin patch pumps, ocular delivery systems and novel systems. Products within each platform are customizable to address specific customer, drug and patient requirements. Unilife's global headquarters and manufacturing facilities are located in York, PA. For more information, visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device. General: UNIS-G Forward-Looking Statements This press release contains forward-looking statements. All statements that address operating performance, or other events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/un...-300136764.html SOURCE Unilife Corporation
  15. p { margin-bottom: 0.25cm; line-height: 120%; } OK I made a mess of that so here it is typed Rig count overview and summary usa 21 august 2015 885 up 1 change from last year down 1011 canada 21 august 2015 208 down 3 change from last year down 197 international july 2015 down 28 change from last year down 264
  16. U.S.21 August 2015885+114 August 2015-101121 August 2014Canada21 August 2015208-314 August 2015-19721 August 2014International July 20151118-28June 2015-264July 2014
  17. <h1 class="title module">Rig Count Overview & Summary Count</h1>AreaLast CountCountChange from Prior CountDate of Prior CountChange from Last YearDate of Last Year's CountU.S.21 August 2015885+114 August 2015-101121 August 2014Canada21 August 2015208-314 August 2015-19721 August 2014International July 20151118-28June 2015-264July 2014 http://media.corporate-ir.net/media_files/IROL/79/79687/North%20American.jpg http://media.corporate-ir.net/media_files/IROL/79/79687/International.jpg http://media.corporate-ir.net/media_files/IROL/79/79687/Interactive.jpg http://media.corporate-ir.net/media_files/IROL/79/79687/FAQ.jpgBaker Hughes has issued the rotary rig counts as a service to the petroleum industry since 1944, when Hughes Tool Company began weekly counts of U.S. and Canadian drilling activity. Hughes initiated the monthly international rig count in 1975. The North American rig count is released weekly at noon central time on the last day of the work week. The international rig count is released on the fifth working day of each month. The Baker Hughes Rig Counts are an important business barometer for the drilling industry and its suppliers. When drilling rigs are active they consume products and services produced by the oil service industry. The active rig count acts as a leading indicator of demand for products used in drilling, completing, producing and processing hydrocarbons. Baker Hughes Rig Counts are published by major newspapers and trade publications, are referred to frequently by journalists, economists, security analysts and government officials, and are included in many industry statistical reports. Because they have been compiled consistently for 70 years, Baker Hughes Rig Counts also are useful in historical analysis of the industry. The working rig location information is provided in part by RigData.
  18. arty I know where you are coming from having spent a small part of my 63 years living in a country that activley suppressed the media I am deeply concerned for the future of democracy in australia when there are demands for unpopular in some circles opinions to be suppressed . The fact that their are individuals who would even consider this is a worrying trend of intolerance that if carried out would leave australia a lesser nation.
  19. It may be that Barton sold because he intended to put the money into one of his other companies which he has been doing . The company is KRC he says it has great future on a mining programme for this year I have considerable doubts disclosure I hold KRC but not PYC
  20. http://www.reuters.com/article/2015/03/05/...N0M10Z420150305 ISIS has torched one of the fields they controlled as Iraqi forces approach
  21. pacestick

    UNS

    It looks like profit taking has taken over and holders will have to wait on the next announcement of a contract to see another surge in price . Expect the Nasdaq shorts to make the most of the time between now and then and push the SP south
  22. pacestick

    UNS

    given last nights nasdaq trading we could see 59 or 60 cents today. With the possibility that theer will be a further rise tomorrow
  23. pacestick

    UNS

    This should catapult the company into profit over the next few years and the medimmine contract could be as big
  24. pacestick

    UNS

    September 9, 2014 Unilife Corporation Announces Financial Results For the Fourth Quarter and Full Fiscal Year 2014 YORK, Pa., Sept. 9, 2014 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS; ASX: UNS), a developer and supplier of injectable drug delivery systems, today announced its financial results for the fiscal fourth quarter and full fiscal year ending June 30, 2014. Recent Highlights Revenue for the Full Fiscal Year of 2014 was $14.7 million, an increase of approximately $12 million or over 400% compared to the prior year. Deferred revenue, which is cash that has been collected and is expected to be recognized within the coming 24 months, for the Full Fiscal Year of 2014 increased to $13.3 million.Cash receipts from customers were $23.7 million for the Full Fiscal Year of 2014, an increase of $22.5 million compared to the prior year.The net operating cash flow loss was narrowed by 20% over the year before, despite a significant increase in R&D investments. Over half of the Company's total annual operating expenses were invested in R&D during the Full Fiscal Year of 2014.At the end of the fourth quarter of Fiscal Year 2014, Unilife had 12 active customer programs, an increase of two programs since the end of the prior quarter, across all six of its product platforms.Since July 1, 2014, Unilife has commenced commercial sales of the Unifill® syringe utilizing an existing commercial manufacturing line. Commercial sales of other products from the Unifill family, including the Unifill Finesse® and the Unifill Nexus™, are scheduled to commence during the middle of the 2015 fiscal year on additional manufacturing lines that are either in the process of being configured or are now operational and in the process of being qualified. Mr. Alan Shortall, Chairman and CEO of Unilife, commented: "Fiscal 2014 was a year of rapid growth in revenue, customers, supply agreements and production capabilities. Having made significant investments in R&D during the last three years, we have achieved a critical mass in product range, capabilities and industry expertise. Those investments are now generating revenue at an attractive growth rate as we enter into and execute upon supply agreements with a growing number of pharmaceutical customers." "During Fiscal Year 2015, we look forward to achieving significant growth in revenue via commercial sales, customization fees and upfront payments from a multitude of customers and active programs. In parallel, we expect to increase capital expenditures in response to growing customer demand while moderating our investments in R&D and keeping SG&A largely stable. We also look forward to completing a number of additional significant supply agreements, which have taken longer than originally anticipated to complete but are now approaching the finish line. Based upon current cash on hand including the recently completed ATM, along with scheduled payments under existing and imminent agreements, we feel confident that we will have sufficient cash to offset our full year operating activities for fiscal 2015," Mr. Shortall concluded. Financial Results for the Full Fiscal Year 2014 Revenue for the Full Fiscal Year of 2014 was $14.7 million, compared to $2.7 million for the same period in 2013. Deferred revenue increased to $13.3 million as of June 30, 2014. The Company's net loss for the Full Fiscal Year of 2014 was $57.9 million, or $0.59 per share, compared to a net loss of $63.2 million, or $0.78 per share, for fiscal year 2013. Adjusted net loss for the Full Fiscal Year of 2014 was $38.8 million, or $0.40 per share, compared to $38.0 million or $0.47 per share for the prior year. Adjusted net loss excludes non-cash share-based compensation expense, depreciation and amortization, interest expense and the change in fair value of financial instruments. Unilife reported $10.8 million in total cash and restricted cash at the end of Fiscal Year 2014, which ended on June 30, 2014. This does not include $12.4 million in net proceeds generated through the completion of our ATM facility in August 2014, or other cash receipts generated by customers since July 1, 2014. Conference Call Information Management has scheduled a conference call for 4:30 p.m. U.S. EDT on Tuesday, September 9, 2014, (Wednesday, September 10, 2014 at 6:30 a.m. AEST), to review the Company's financial results, customer partnerships and future outlook. The conference call and accompanying slide presentation will be broadcast over the Internet as a "live" listen-only Webcast. An archive of the presentation and webcast will be available for 30 days after the call. To listen, please go to: http://ir.unilife.com/events.cfm. About Unilife Corporation Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife's broad portfolio of proprietary technologies includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, ocular delivery systems and novel systems. Each of these innovative and highly differentiated platforms can be customized to address specific customer, drug and patient requirements. Unilife's global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information, please visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device. Forward-Looking Statements This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission. Non-GAAP Financial Measures U.S. securities laws require that when we publish any non-GAAP financial measure, we disclose the reason for using the non-GAAP measure and provide reconciliation to the most directly comparable GAAP measure. The presentation of adjusted net income (loss) and adjusted net income (loss) per share are non-GAAP measures. Adjusted net income (loss) represents net income (loss) calculated in accordance with U.S. GAAP as adjusted for the impact of share-based compensation expense, depreciation and amortization and interest expense. Management believes the presentation of adjusted net income (loss) and adjusted net income (loss) per share provides useful information because these measures enhance its own evaluation, as well as investor's understanding, of the Company's core operating and financial results. Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. A reconciliation of net income (loss) to adjusted net income (loss) is included in the attached table. General: UNIS-G Investor Contacts (US): Analyst Enquiries Investor Contacts (Australia) Todd Fromer / Garth Russell Leigh Salvo Jeff Carter KCSA Strategic Communications Westwicke Partners Unilife Corporation P: + 1 212-682-6300 P: + 1 415-513-1281 P: + 61 2 8346 6500
  25. pacestick

    KRC

    "King River Copper Limited (“King River†or “the Companyâ€ÂÂÂÂÂ) (ASX: KRC) has noted today the increased interest and price movement of its shares. The Company is not aware of any material information that has not been previously disclosed to shareholders. The Company has not yet commenced drilling. The first drilling is planned to commence next Wednesday, May 28 at the shear zone on Chapman Hills, followed by a diamond drilling program at the Chapman outcrops. The phase 1 drilling program will be spread over 7 different locations and is expected to take up to 6 weeks. All drill core will be stored on site, then delivered to Perth early July for cutting and assaying. Recent bulldozer work providing access to the 2 drill site locations at Chapman outcrops has exposed further copper carbonate (malachite) in quartz veins and breccias that has been lodged for assaying. Any assay results received that are viewed by the company to be material will be released on receipt. The Chairman, Anthony Barton is also presenting the company to a large group of London investors in the evening of May 28. There is no other information known to the company."
×
×
  • Create New...